Nimbus to Present SIK2 Arthritis Data
Nimbus Therapeutics will present preclinical rheumatoid arthritis data on selective SIK2 inhibition at ACR Convergence 2026 in Orlando.
Updated on Nov. 5, 2026 in Arthritis
Nimbus Therapeutics, a computational drug discovery company headquartered in Boston, will present preclinical data on selective SIK2 inhibitors for rheumatoid arthritis at ACR Convergence 2026, held November 6-11 in Orlando, Florida. The poster session is scheduled for Sunday, November 8, 2026.
Why it matters
In a mouse collagen-induced arthritis model, selective SIK2 inhibitors dosed after disease onset reduced paw swelling, joint inflammation and synovial hyperplasia to levels comparable to etanercept and upadacitinib. The findings point to SIK2 as a potential target for rheumatoid arthritis, a field where Nimbus is seeking to advance its discovery work.
The preclinical results come from a mouse collagen-induced arthritis model, with selective SIK2 inhibitors compared against etanercept and upadacitinib. Whether the effect holds in humans has not been reported.
The players
Nimbus Therapeutics
Nimbus Therapeutics is a computational drug discovery company based in Boston, Massachusetts, that develops small-molecule therapies.
Scott Daigle
Scott Daigle is Senior Director of Translational Medicine at Nimbus Therapeutics and will present the SIK2 poster at the conference.
The details
Nimbus' SIK2 inhibitors act on two mechanisms relevant to rheumatoid arthritis: inflammatory responses in human immune cells and osteoclast differentiation. Scott Daigle, Senior Director of Translational Medicine at Nimbus, will present the poster.
Timeline
November 6-11, 2026: ACR Convergence 2026 takes place in Orlando, Florida.
Sunday, November 8, 2026, 10:30 a.m. - 12:30 p.m. ET: Poster session presenting the SIK2 rheumatoid arthritis data.
Big Picture
The SIK2 data are being shared at ACR Convergence, the annual meeting of the American College of Rheumatology, where researchers compare new mechanisms against established treatments such as etanercept and upadacitinib. The poster adds a novel target to that comparison.
The preclinical results do not change current treatment options for rheumatoid arthritis patients. Readers should expect that any new therapy would need human clinical trials before becoming available.
The takeaway
Preclinical animal results can show promise for a new drug target, but they must be confirmed in human studies before they affect patient care. Watch for future clinical data from Nimbus before drawing conclusions about SIK2 inhibitors for rheumatoid arthritis.
What happens next
Nimbus will present the SIK2 rheumatoid arthritis poster at ACR Convergence 2026 on Sunday, November 8, 2026, from 10:30 a.m. to 12:30 p.m. ET in Orlando.
Further reading
Explore more Arthritis coverage on Wisevoter.
Source note: This article includes information reported by Firstwordpharma.
